Skip to content
Review

A safety review of jak inhibitors for managing alopecia areata.

Sep 2026 · Expert Opinion on Drug Safety · 0 citations · 111 references
Medicine

Abstract

INTRODUCTION Alopecia areata (AA) is a chronic immune-mediated disorder associated with substantial psychosocial burden. Janus kinase (JAK) inhibitors have transformed the treatment of moderate-to-severe AA, but concerns regarding their long-term safety remain, particularly because class warnings are largely derived from higher-risk rheumatologic populations. AREAS COVERED This review evaluates the safety of JAK inhibitors used for AA in adults, with emphasis on baricitinib, ritlecitinib, and deuruxolitinib, alongside relevant evidence for other JAK inhibitors. PubMed/MEDLINE, Embase, and Scopus were searched from database inception through April 2026 for relevant clinical trials, long-term studies, meta-analyses, real-world studies, and pharmacovigilance reports. Adolescent data were considered only when reported within mixed adult-adolescent populations or pooled safety analyses. Infection, malignancy, cardiovascular and thromboembolic risk, laboratory abnormalities, special populations, and practical monitoring considerations are reviewed. EXPERT OPINION Current evidence suggests that serious adverse outcomes are uncommon in appropriately selected adults with AA and that risks observed in older, comorbidity-enriched rheumatologic populations should not be directly extrapolated to AA. Future management will increasingly depend on individualized risk stratification, long-term disease-specific safety data, and agent-specific rather than class-wide assessment.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.